Effectiveness of janus kinase inhibitors in relapsing giant cell arteritis in real-world clinical practice and review of the literature.
Javier LoriceraToluwalase TofadeDiana Prieto-PeñaSusana Romero-YusteEugenio de MiguelAnne Riveros-FrutosIván Ferraz-AmaroEztizen LabradorOlga MaizElena BecerraJavier NarváezEva Galíndez-AgirregoikoaIsmael González-FernándezAna Urruticoechea-AranaÁngel Ramos-CalvoFernando López-GutiérrezSantos CastañedaSebastian H UnizonyRicardo Blanco-AlonsoPublished in: Arthritis research & therapy (2024)
This real-world analysis and literature review suggest that JAKi could be effective in GCA, including in patients failing established glucocorticoid-sparing therapies such as tocilizumab and methotrexate. A phase III randomized controlled trial of upadacitinib is currently ongoing (ClinicalTrials.gov ID NCT03725202).
Keyphrases
- randomized controlled trial
- phase iii
- giant cell
- end stage renal disease
- clinical practice
- multiple sclerosis
- open label
- newly diagnosed
- clinical trial
- ejection fraction
- rheumatoid arthritis
- chronic kidney disease
- study protocol
- systematic review
- peritoneal dialysis
- case report
- patient reported outcomes
- double blind
- phase ii
- disease activity
- low dose
- robot assisted
- rheumatoid arthritis patients
- patient reported
- placebo controlled